Intuitive Surgical, Inc. (NASDAQ:ISRG) Stock Holdings Lessened by Sumitomo Mitsui Trust Holdings Inc.

Sumitomo Mitsui Trust Holdings Inc. decreased its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 1.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,451,414 shares of the medical equipment provider’s stock after selling 17,856 shares during the quarter. Sumitomo Mitsui Trust Holdings Inc. owned approximately 0.41% of Intuitive Surgical worth $579,245,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of ISRG. Vanguard Group Inc. grew its position in Intuitive Surgical by 0.7% in the 3rd quarter. Vanguard Group Inc. now owns 29,868,227 shares of the medical equipment provider’s stock worth $8,730,184,000 after purchasing an additional 196,316 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in Intuitive Surgical by 1.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 16,973,266 shares of the medical equipment provider’s stock valued at $5,726,102,000 after acquiring an additional 272,741 shares during the period. Edgewood Management LLC raised its stake in Intuitive Surgical by 7.9% during the 4th quarter. Edgewood Management LLC now owns 5,131,066 shares of the medical equipment provider’s stock valued at $1,731,016,000 after acquiring an additional 374,667 shares in the last quarter. Fisher Asset Management LLC boosted its position in Intuitive Surgical by 2.0% during the 4th quarter. Fisher Asset Management LLC now owns 4,494,373 shares of the medical equipment provider’s stock worth $1,516,222,000 after acquiring an additional 88,977 shares during the period. Finally, Norges Bank bought a new position in shares of Intuitive Surgical in the fourth quarter worth $1,313,238,000. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Intuitive Surgical Stock Down 0.9 %

Shares of ISRG traded down $3.76 during midday trading on Wednesday, reaching $435.05. 88,405 shares of the stock were exchanged, compared to its average volume of 1,513,350. The company has a market cap of $154.31 billion, a price-to-earnings ratio of 79.21, a P/E/G ratio of 5.75 and a beta of 1.39. The firm has a 50 day simple moving average of $405.17 and a 200-day simple moving average of $384.28. Intuitive Surgical, Inc. has a 12-month low of $254.85 and a 12-month high of $448.10.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, beating analysts’ consensus estimates of $1.40 by $0.10. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The business had revenue of $1.89 billion for the quarter, compared to the consensus estimate of $1.87 billion. During the same quarter last year, the firm earned $1.00 EPS. Intuitive Surgical’s revenue for the quarter was up 11.5% on a year-over-year basis. Research analysts expect that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current fiscal year.

Insider Activity at Intuitive Surgical

In other Intuitive Surgical news, Director Alan J. Levy sold 2,000 shares of the stock in a transaction that occurred on Tuesday, April 23rd. The stock was sold at an average price of $370.70, for a total transaction of $741,400.00. Following the transaction, the director now owns 25,319 shares in the company, valued at $9,385,753.30. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, EVP Myriam Curet sold 5,318 shares of the stock in a transaction that occurred on Tuesday, April 23rd. The stock was sold at an average price of $370.66, for a total value of $1,971,169.88. Following the completion of the sale, the executive vice president now directly owns 298 shares of the company’s stock, valued at $110,456.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Alan J. Levy sold 2,000 shares of the company’s stock in a transaction on Tuesday, April 23rd. The shares were sold at an average price of $370.70, for a total transaction of $741,400.00. Following the transaction, the director now owns 25,319 shares of the company’s stock, valued at $9,385,753.30. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 17,956 shares of company stock valued at $6,927,011. Corporate insiders own 0.80% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. BTIG Research lifted their price objective on shares of Intuitive Surgical from $412.00 to $421.00 and gave the company a “buy” rating in a research note on Friday, April 19th. Jefferies Financial Group lifted their price target on Intuitive Surgical from $365.00 to $375.00 and gave the company a “hold” rating in a research report on Friday, April 19th. Robert W. Baird decreased their target price on Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating for the company in a research note on Friday, April 19th. Citigroup upped their price target on shares of Intuitive Surgical from $428.00 to $462.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. Finally, The Goldman Sachs Group started coverage on shares of Intuitive Surgical in a research note on Thursday, May 30th. They issued a “buy” rating and a $500.00 price objective on the stock. Six investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and an average price target of $404.79.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.